AMGEN and Ro Partner to Improve Access to Obesity Treatments and Address Healthcare Barriers

Amgen and Ro Collaborate to Enhance Access to Obesity Treatments

Amgen, a prominent player in the biopharmaceutical industry, partners with Ro, a direct-to-patient healthcare company, to address significant barriers in accessing obesity treatments. This collaboration focuses on leveraging Ro’s extensive de-identified data to explore the real-world challenges patients and healthcare providers face concerning GLP-1 medications, which are crucial for effective obesity management. Zach Reitano, CEO of Ro, underscores the urgency of this initiative, highlighting the millions of Americans who could benefit from improved access to these therapies. The partnership aims to transform healthcare delivery for obesity treatment by identifying and addressing gaps in insurance coverage that currently hinder patient access.

The research effort will delve into critical issues such as insurance coverage for GLP-1 medications and trends in prior authorizations required for treatment. Previous studies have largely centered on policy-level data, leaving a gap in understanding how these factors affect patient experiences at the ground level. By investigating these nuances, the collaboration seeks to empower both patients and healthcare providers, ensuring that those who are clinically eligible for obesity treatments can effectively access the therapies they need. This initiative aligns with Amgen's commitment to observational research, which plays a vital role in advancing patient care and informing future innovations in therapy development.

Furthermore, the partnership aims to dismantle existing barriers to care, improving the overall patient experience and paving the way for wider access to next-generation obesity treatments. As obesity rates continue to rise in the United States, this collaboration represents a significant step toward creating a more equitable healthcare landscape. By focusing on real-world data and patient-centered outcomes, Amgen and Ro are positioned to drive meaningful change in the treatment of obesity, ultimately enhancing patient outcomes and quality of life.

In a related development, Amgen also highlights its promising obesity drug, MariTide, which is designed for monthly use rather than the more common weekly injections. CEO Bob Bradway emphasizes the importance of patient persistence in therapy adherence, noting that clinical trials show patients can maintain weight loss for up to two years. This innovation reflects Amgen's dedication to developing effective obesity treatments that improve the patient experience and engagement.

Additionally, Amgen's recent acquisition of Horizon Therapeutics is progressing well, aligning with its expertise in biologics and autoimmune conditions. The integration of Horizon's medications, which target autoimmune disorders, is expected to enhance Amgen's therapeutic portfolio while paving the way for ongoing exploration of new diseases that could benefit from these advanced treatments.